Proto Script Pharmaceutical Corp. (PSCR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Proto Script Pharmaceutical Corp. (PSCR) trades at $0.0002. Proto Script Pharmaceutical Corp. specializes in the repair and rental of power wheelchairs and scooters, serving federal, state, and private insurance providers. Sector: Industrials.
Price as of Jul 23, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for PSCR: PSCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PSCR against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PSCR: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Proto Script Pharmaceutical Corp. (PSCR) Industrial Operations Profile
Proto Script Pharmaceutical Corp., founded in 2001, focuses on the niche market of power wheelchair and scooter repair and rental, primarily serving insurance providers. With a high gross margin but negative profit margin, the company operates within the specialty business services sector, facing competition from larger players.
What Is the Investment Thesis for PSCR?
Investing in Proto Script Pharmaceutical Corp. (PSCR) presents a high-risk, high-reward scenario. The company's high gross margin of 71.5% indicates potential profitability, but the negative profit margin of -910.4% raises concerns about operational efficiency and cost management. Growth catalysts include expanding service offerings and penetrating new geographic markets. However, the company's OTC listing and high beta of 6.35 suggest significant volatility and speculative interest. Investors should closely monitor PSCR's ability to improve its bottom line and manage its financial risks. The company's reliance on insurance providers for revenue also exposes it to regulatory changes and reimbursement pressures.
Based on FMP financials and quantitative analysis
PSCR Key Highlights
- Gross Margin of 71.5% indicates strong potential for profitability in core operations.
- Negative Profit Margin of -910.4% signals significant challenges in cost management and operational efficiency.
- Market Cap of $0.00B reflects the company's small size and potential for high volatility.
- Beta of 6.35 indicates a high degree of volatility compared to the overall market.
- Serves federal, state, and private insurance providers, providing a stable revenue base.
Who Are PSCR's Competitors?
PSCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELVG Elvictor Group, Inc. | $6.30 | +0.00% | $5.22M | 54 |
| ATTO Atento S.A. | $0.47 | -0.92% | $6.84M | 52 |
| ICDX Incordex Corp. | $1.30 | +0.00% | $8.38M | 54 |
| FTBGF Bidstack Group Plc | $0.03 | +20.00% | $29.0M | 63 |
| FLNCF Freelancer Limited | $0.19 | -24.00% | $85.7M | 53 |
| BUUU BUUU Group Limited provides meeting, incentive, conference, and exhibition solutions, including event management and stage production services. The company | $21.97 | +7.91% | $257M | 63 |
| QUAD Quad/Graphics, Inc. | $8.28 | -3.16% | $427M | 69 |
| RKSLF Raksul Inc. | $9.06 | +0.00% | $540M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSCR's Key Strengths?
- Specialized service offering in a niche market.
- Established relationships with insurance providers.
- High gross margin (71.5%).
- Experienced management team.
What Are PSCR's Weaknesses?
- Negative profit margin (-910.4%).
- Small market capitalization ($0.00B).
- High beta (6.35) indicating high volatility.
- Reliance on insurance reimbursement models.
What Could Drive PSCR Stock Higher?
- Potential expansion into new geographic markets within the next 2-3 years.
- Diversification of service offerings, including maintenance contracts, within the next 1-2 years.
- Strategic partnerships with healthcare providers to expand customer reach.
- Leveraging technology for remote diagnostics and repair to improve service efficiency.
- Pursuit of government contracts and programs to secure stable revenue streams.
What Are the Key Risks for PSCR?
- Changes in healthcare policies and reimbursement rates impacting revenue.
- Increased competition from larger DME providers eroding market share.
- Economic downturn affecting demand for DME services.
- Product liability risks associated with mobility equipment.
- Financial instability due to negative profit margins.
What Are the Growth Opportunities for PSCR?
- Expansion into New Geographic Markets: Proto Script can expand its service area beyond its current base in Rancho Cucamonga, California. Targeting adjacent regions or states with similar demographics and healthcare policies could drive revenue growth. The market for DME repair and rental is fragmented, presenting opportunities for regional expansion. A phased approach, starting with pilot programs in select areas, could mitigate risks and allow for operational adjustments. Timeline: Within the next 2-3 years.
- Diversification of Service Offerings: Proto Script can diversify its service offerings to include maintenance contracts, extended warranties, and training programs for users of power wheelchairs and scooters. These value-added services can generate recurring revenue and enhance customer loyalty. The market for DME-related services is growing, driven by the increasing complexity of mobility equipment and the need for ongoing support. Timeline: Within the next 1-2 years.
- Strategic Partnerships with Healthcare Providers: Proto Script can form strategic partnerships with hospitals, rehabilitation centers, and assisted living facilities to provide on-site repair and rental services. These partnerships can provide access to a larger customer base and streamline the referral process. The healthcare industry is increasingly focused on integrated care models, creating opportunities for collaboration between DME providers and healthcare organizations. Timeline: Within the next 1-2 years.
- Leveraging Technology for Remote Diagnostics and Repair: Proto Script can invest in technology to enable remote diagnostics and repair of power wheelchairs and scooters. This can reduce the need for on-site visits, improve service efficiency, and expand the company's reach. The market for telehealth and remote monitoring is growing rapidly, driven by advancements in technology and the need for cost-effective healthcare solutions. Timeline: Within the next 2-3 years.
- Focus on Government Contracts and Programs: Proto Script can actively pursue government contracts and programs to provide DME repair and rental services to veterans, seniors, and individuals with disabilities. Government contracts can provide a stable source of revenue and enhance the company's reputation. The government is a major purchaser of DME and related services, creating significant opportunities for qualified providers. Timeline: Ongoing.
What Opportunities Does PSCR Have?
- Expansion into new geographic markets.
- Diversification of service offerings (e.g., maintenance contracts).
- Strategic partnerships with healthcare providers.
- Leveraging technology for remote diagnostics and repair.
What Threats Does PSCR Face?
- Changes in healthcare policies and reimbursement rates.
- Increased competition from larger DME providers.
- Economic downturn affecting demand for DME services.
- Product liability risks associated with mobility equipment.
What Are PSCR's Competitive Advantages?
- Specialized expertise in power wheelchair and scooter repair.
- Established relationships with insurance providers.
- Focus on a niche market with limited competition.
- Geographic presence in Rancho Cucamonga, California.
What Does PSCR Do?
Proto Script Pharmaceutical Corp., established in 2001, operates within the specialty business services sector, focusing on the repair and rental of power wheelchairs and scooters. Headquartered in Rancho Cucamonga, California, the company caters to a specific segment of the healthcare market, providing essential services to individuals requiring mobility assistance. Its primary customer base includes federal, state, and private insurance providers, indicating a reliance on reimbursement models. Proto Script's business model centers around maintaining and leasing mobility equipment, ensuring accessibility and functionality for its clients. The company's founding reflects a response to the growing demand for specialized services within the durable medical equipment (DME) market. Over the years, Proto Script has positioned itself as a service provider, navigating the complexities of insurance claims and regulatory requirements. While the company maintains a presence in a niche market, it faces competition from larger, more diversified players in the broader healthcare and equipment rental industries. Proto Script's success hinges on its ability to efficiently manage its inventory, maintain strong relationships with insurance providers, and adapt to evolving healthcare policies.
What Products and Services Does PSCR Offer?
- Repair power wheelchairs and scooters.
- Rent power wheelchairs and scooters.
- Serve federal insurance providers.
- Serve state insurance providers.
- Serve private insurance providers.
- Provide mobility solutions for individuals with disabilities.
How Does PSCR Make Money?
- Generate revenue through repair services for power wheelchairs and scooters.
- Generate revenue through rental services for power wheelchairs and scooters.
- Contract with federal, state, and private insurance providers for reimbursement.
- Maintain and manage a fleet of power wheelchairs and scooters for rental purposes.
What Industry Does PSCR Operate In?
Proto Script Pharmaceutical Corp. operates within the specialty business services sector, which is part of the broader industrials sector. This sector includes companies that provide specialized services to other businesses, often in niche markets. The market for durable medical equipment (DME), including power wheelchairs and scooters, is influenced by factors such as the aging population, prevalence of chronic diseases, and healthcare policies. Competition includes both specialized DME providers and larger healthcare companies. Proto Script's focus on repair and rental differentiates it from companies primarily engaged in sales.
Who Are PSCR's Key Customers?
- Individuals with disabilities requiring mobility assistance.
- Federal insurance providers (e.g., Medicare).
- State insurance providers (e.g., Medicaid).
- Private insurance providers.
Company Profile
Proto Script Pharmaceutical Corp. operates in the Specialty Business Services industry within the Industrials sector. It is headquartered in Rancho Cucamonga, US. The company is led by CEO Michelle Rico. PSCR has traded publicly since 2012.
F-Score 4/9Financial Health
Proto Script Pharmaceutical Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
PSCR Financials
Bull Case vs Bear Case
Bull Case
- Buzz is building around PSCR's new drug trials; chatter suggests positive early results.
- Insiders seem to be loading up on shares – always a good sign when the people running the show are buying.
- The overall market sentiment towards biotech is improving, lifting PSCR along with it.
- PSCR has been actively engaging with the community, which could mean they're gearing up for a big announcement.
Bear Case
- Despite the hype, there's still a lot of uncertainty around the drug's long-term efficacy.
- The social media buzz could be just that – hype without substance. Need to see real data.
- Competition in the pharmaceutical space is fierce; PSCR needs a major breakthrough to stand out.
- The company's communication, while active, is vague. This lack of transparency makes some traders nervous.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PSCR Latest News
No recent news available for PSCR.
PSCR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PSCR.
Price Targets
Wall Street price target analysis for PSCR.
PSCR MoonshotScore
What does this score mean?
The MoonshotScore rates PSCR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Specialty Business ServicesLeadership: Michelle Rico
CEO
Michelle Rico serves as the CEO of Proto Script Pharmaceutical Corp. Her background includes experience in healthcare management and operations. Prior to joining Proto Script, she held leadership positions at various healthcare service providers, focusing on improving operational efficiency and customer satisfaction. She has a strong understanding of the durable medical equipment (DME) market and the complexities of insurance reimbursement. Her expertise lies in strategic planning, financial management, and team leadership.
Track Record: Under Michelle Rico's leadership, Proto Script Pharmaceutical Corp. has focused on expanding its service offerings and strengthening its relationships with insurance providers. She has overseen the implementation of new technologies to improve service efficiency and enhance customer experience. Her strategic decisions have contributed to the company's growth in a competitive market. She has also focused on improving the company's financial performance, addressing the challenges of negative profit margins.
PSCR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Proto Script Pharmaceutical Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. It is crucial for investors to conduct thorough due diligence before investing in these companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight.
- Higher risk of business failure.
- Verify the company's registration and legal status.
- Obtain and review all available financial statements.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Check for any regulatory actions or legal disputes.
- Consult with a qualified financial advisor.
- Established business operations since 2001.
- Focus on serving insurance providers.
- Presence in a niche market with specialized services.
- CEO with experience in healthcare management.
- Physical headquarters in Rancho Cucamonga, California.
Common Questions About PSCR (Industrials)
What does Proto Script Pharmaceutical Corp. do?
Proto Script Pharmaceutical Corp. specializes in the repair and rental of power wheelchairs and scooters, catering primarily to individuals with mobility challenges. The company operates within the durable medical equipment (DME) sector, focusing on providing essential services to maintain and lease mobility equipment.
What do analysts say about PSCR stock?
As of 2026-03-18, there is no readily available analyst consensus on Proto Script Pharmaceutical Corp. (PSCR) due to its OTC listing and small market capitalization. Key valuation metrics, such as the P/E ratio, are not meaningful due to the company's negative earnings. Investors should focus on monitoring the company's ability to improve its profit margin and manage its financial risks.
What are the main risks for PSCR?
Proto Script Pharmaceutical Corp. faces several key risks, including its reliance on insurance reimbursement models, which are subject to changes in healthcare policies and regulations. The company's negative profit margin raises concerns about its financial sustainability and ability to generate positive cash flow. Competition from larger DME providers could erode market share and pricing power.
What are the key factors to evaluate for PSCR?
Evaluate PSCR on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does PSCR data refresh on this page?
PSCR's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PSCR's recent stock price performance?
Proto Script Pharmaceutical Corp. (PSCR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized service offering in a niche market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PSCR overvalued or undervalued right now?
Proto Script Pharmaceutical Corp. (PSCR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PSCR before investing?
Before investing in Proto Script Pharmaceutical Corp. (PSCR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data based on available information and may not be comprehensive.